The global market for pulmonary drug delivery technologies reached $32.4 billion in 2013 and is expected to grow to $43.9 billion in 2018, with a compound annual growth rate (CAGR) of 6.2%.
This report provides:
- A detailed overview and thorough analysis of the present and future global markets for pulmonary drug delivery technologies
- Analyses of global market trends, with data from 2012 and 2013, and projections of compound annual growth rates (CAGRs) through 2018.
- Identification of emerging pulmonary drug delivery technologies, particularly with regard to inhaled drug delivery systems
- Information on technological developments, product innovations, and recent strategic industry activities of major players across different product categories
- Examination of devices currently being used for drug delivery to the lungs, new developments, spending trends, and revenue prospects for these technologies
- Comprehensive profiles of leading companies in the industry.
GLOBAL MARKET FOR PULMONARY DRUG DELIVERY TECHNOLOGIES, THROUGH 2018
Source: BCC Research
Download Report Overview
STUDY GOALS AND OBJECTIVES
This BCC Research market research report, Pulmonary Drug Delivery Systems: Technologies and Global Markets, provides a detailed overview and detailed analysis of the present and future global market for pulmonary drug delivery technologies.
This report analyzes in detail the pulmonary drug delivery technologies currently in use and that are available. This report includes products in this market and detailed analyses of the markets and competitive environments. It also analyzes current and future market prospects.
The report provides a comprehensive review of emerging pulmonary drug delivery technologies, particularly with regard to inhaled drug delivery systems. The analysis reviews technological developments, product innovations and recent strategic industry activities of major players across different product categories. It reviews their strengths and weaknesses, opportunities and the threats facing various devices and drugs in this market space.
The report also reviews developments already on the market, major issues involved in the research and development (R&D) of more effective drug/devices for drug delivery to the lungs and new products in development.
REASONS FOR DOING THE STUDY
Pulmonary drug delivery originated as a more relevant alternative for delivering drugs to the lungs. Respiratory conditions such as asthma, chronic obstructive pulmonary (COPD) and emphysema are therapeutic areas of the pulmonary space. Recent technological advancements have applied the application of pulmonary devices to the treatment of nonrespiratory conditions also such as diabetes and migraines.
The recent trends and research in the formulating sector have grown tremendously and increased sales of dry powder inhalers (DPIs), and slowly replaced metered-dose inhalers (MDIs).
Pulmonary delivery of drugs for the treatment of respiratory diseases gives a faster, simpler and easier therapeutic effect compared to systemic treatments for these indications. In addition, it also reduces side effects associated with many drugs. Still, understanding the trends in this market, and currently available drug/device combinations and improving them and eliminating risks and problems, will help in faster, effective drug delivery to the lungs.
SCOPE AND FORMAT
The report reviews global markets for pulmonary drug delivery technologies and new developments, and forecasts trends for use of current drug/devices systems for pulmonary drug delivery and safety and toxicology through 2018. The report presents important drug/device and technologies, latest developments, market share by drug/device and drug and disease type, current products on the market, market share by company or product, and statistical information for types of respiratory diseases prevalent worldwide, with special emphasis on the U.S. market.
The report also includes current issues and trends affecting the industry including costs, and factors influencing demand will be discussed. The report covers products in development, new technologies, trends, alliances, patents and mergers. The report offers market data with respect to segments and geography. It also provides market trends with respect to drivers, restraints and opportunities.
This report is an exhaustive study of the worldwide pulmonary drug delivery device market, giving crucial statistics and analysis on existing technologies, the latest trends, market structure, market size, key drug segments, important trends in technology development, influencers, major opportunities, and market shares of key players and inhaled drug/device and drug. This report may prove crucial for drug development companies in the pulmonary drug delivery space, such as potential investors in the concerned sector. This report discusses drug/device currently being used for pulmonary drug delivery to the lungs, new developments surrounding these systems, current spending trends and revenue prospects for these technologies. The report provides relevant market data for 2011 to 2018 and also covers commercial prospects for pulmonary devices and current inhalers in use and their future.
Both primary and secondary research methodologies were used in preparing this report. Secondary sources include books, newspapers, trade journals, white papers, industry portals, interviews, government agencies, trade associations, industry news, and developments and access to paid databases. The base year of the report is 2013, with forecast data provided through 2018. Historical, base year and forecast data are provided for each market segment of this report. The report provides a comprehensive review of emerging pulmonary drug delivery technologies, particularly with regard to inhaled drug delivery systems (both drug and device combined). The analysis reviews new technological developments, product innovations/introductions and recent strategic industry activities of major players across various product categories. Growth rates are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in R&D and current product growth.
Usha Nagavarapu is an experienced pharmaceutical professional with scientific and alliance development experience. She has more than 10 years of drug and device product development and alliance management experience. She has managed preclinical discovery programs from target identification through design of Phase I testing, including Investigational New Drug (IND)-enabling studies, and assisted out-licensing and portfolio development activities. Strong focus areas include oncology, dermatology, and cardiovascular diseases. She also has extensive experience working with early startups to fulfill operational obligations while minimizing overall operational cost and burdens.
BCC RESEARCH WEBSITE
The BCC Research website, located at www.bccresearch.com, enables visitors to:
- Conduct key word searches.
- Examine the complete BCC Research catalog of market research reports and place direct orders.
- Read announcements of recently published reports.
- View titles of near-term upcoming reports.
- Sign up to receive email notifications when reports are published in selected categories.
- Contact BCC Research for additional information.
The information developed in this report is intended to be as reliable as possible at the time of publication and is of a professional nature. This information does not constitute managerial, legal or accounting advice, nor should it be considered as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is speculative in nature. BCC Research and the author assume no responsibility for any loss or damage that might result from reliance on the reported information or from its use.
Download Report Overview